Drug reference

tubocurarine

Competitive neuromuscular blocking agent (Benzylisoquinoline type) · Neuromuscular blocker

Competitive neuromuscular blocking agent (Benzylisoquinoline type)Neuromuscular blocker

CDSCO approved

EXCRETION

—

not curated

INTERACTIONS

10 major

SEVERE in our sources

PREGNANCY

—

not curated

Top interactionssee all 11 →

AmikacinSevereDatabaseDDInter
Botulinum Toxin Type ASevereDatabaseDDInter
Botulinum Toxin Type BSevereDatabaseDDInter
ColistimethateSevereDatabaseDDInter

Mechanism

Binds to the nicotinic acetylcholine receptor in skeletal muscle (Nm) and competitively blocks the binding of acetylcholine.

Indications

Adjuvant in surgical anesthesia to obtain relaxation of skeletal muscleFacilitate endotracheal intubation

Dosing

Adult: 0.6 mg/kg (initiation); 0.25–0.5 mg/kg (intermittent injection); 2–3 µg/kg/min (continuous infusion)

Pharmacokinetics

Onset

4–6 min

Duration

80 min

Excretion

Renal and hepatic elimination

Contraindications

Not used now due to prominent histamine releasing, ganglion blocking and cardiovascular actions as well as long duration of paralysis needing pharmacological reversal.

Side effects

Common

Significant fall in blood pressure (due to ganglionic blockade, histamine release, and reduced venous return)FlushingBronchospasmIncreased respiratory secretions

Serious

Partial blockade at autonomic ganglia and adrenal medulla, leading to a fall in blood pressure and tachycardia
Histamine release (e.g., bronchospasm, hypotension, excessive bronchial and salivary secretion)